1177 related articles for article (PubMed ID: 10605194)
41. Monotherapy for empirical management of febrile neutropenic patients.
Rubin M; Pizzo PA
NCI Monogr; 1990; (9):111-6. PubMed ID: 2160613
[TBL] [Abstract][Full Text] [Related]
42. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
[TBL] [Abstract][Full Text] [Related]
43. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.
Kwon KT; Cheong HS; Rhee JY; Wi YM; Ryu SY; Heo ST; Moon CS; Ki HK; Kim KH; Jung CW; Peck KR; Song JH
Jpn J Clin Oncol; 2008 Jan; 38(1):49-55. PubMed ID: 18203711
[TBL] [Abstract][Full Text] [Related]
44. [Infection in neutropenic cancer patients--etiology, microbiological diagnostics, treatment].
Durnaá B; Dzierzanowska D
Wiad Lek; 2006; 59(7-8):506-11. PubMed ID: 17209349
[TBL] [Abstract][Full Text] [Related]
45. Management of infections during intensive treatment of hematologic malignancies.
Maschmeyer G; Hiddemann W; Link H; Cornely OA; Buchheidt D; Glass B; Adam D
Ann Hematol; 1997; 75(1-2):9-16. PubMed ID: 9322678
[TBL] [Abstract][Full Text] [Related]
46. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
[TBL] [Abstract][Full Text] [Related]
47. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
Slobbe L; Waal Lv; Jongman LR; Lugtenburg PJ; Rijnders BJ
Eur J Cancer; 2009 Nov; 45(16):2810-7. PubMed ID: 19647995
[TBL] [Abstract][Full Text] [Related]
48. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee.
Tam CS; O'Reilly M; Andresen D; Lingaratnam S; Kelly A; Burbury K; Turnidge J; Slavin MA; Worth LJ; Dawson L; Thursky KA;
Intern Med J; 2011 Jan; 41(1b):90-101. PubMed ID: 21272173
[TBL] [Abstract][Full Text] [Related]
49. [Management of febrile neutropenic patients].
Takata T; Tamura K
Gan To Kagaku Ryoho; 2006 Jan; 33(1):13-8. PubMed ID: 16410691
[TBL] [Abstract][Full Text] [Related]
50. [Empiric antibiotic therapy for treatment of infection in patients with severe neutropenia].
Bajko G; Kubiak A; Hansz J
Acta Haematol Pol; 1995; 26(1):15-26. PubMed ID: 7747558
[TBL] [Abstract][Full Text] [Related]
51. The use of aminoglycosides in neutropenic patients.
Cometta A; Glauser MP
Schweiz Med Wochenschr Suppl; 1996; 76():21S-27S. PubMed ID: 8677415
[TBL] [Abstract][Full Text] [Related]
52. Bacterial infections in low-risk, febrile neutropenic patients.
Kamana M; Escalante C; Mullen CA; Frisbee-Hume S; Rolston KV
Cancer; 2005 Jul; 104(2):422-6. PubMed ID: 15937905
[TBL] [Abstract][Full Text] [Related]
53. [Antibiotic therapy in leukopenia].
Böhme A; Shah PM; Stille W; Hoelzer D
Praxis (Bern 1994); 1998 Sep; 87(36):1120-5. PubMed ID: 9782739
[TBL] [Abstract][Full Text] [Related]
54. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients.
Oude Nijhuis C; Kamps WA; Daenen SM; Gietema JA; van der Graaf WT; Groen HJ; Vellenga E; Ten Vergert EM; Vermeulen KM; de Vries-Hospers HG; de Bont ES
J Clin Oncol; 2005 Oct; 23(30):7437-44. PubMed ID: 16234511
[TBL] [Abstract][Full Text] [Related]
55. High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy.
Ritchie S; Palmer S; Ellis-Pegler R
Intern Med J; 2007 Jan; 37(1):26-31. PubMed ID: 17199841
[TBL] [Abstract][Full Text] [Related]
56. Empiric antifungal therapy in patients with febrile neutropenia.
Ferrara JJ; MacDougall C; Gallagher JC
Pharmacotherapy; 2011 Apr; 31(4):369-85. PubMed ID: 21449626
[TBL] [Abstract][Full Text] [Related]
57. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
58. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.
Klastersky J; Paesmans M; Georgala A; Muanza F; Plehiers B; Dubreucq L; Lalami Y; Aoun M; Barette M
J Clin Oncol; 2006 Sep; 24(25):4129-34. PubMed ID: 16943529
[TBL] [Abstract][Full Text] [Related]
59. [Empirical antibiotic therapy in febrile neutropenic patients with acute leukemia].
Yabe H; Nakamura F; Ishikawa T; Nagai K; Nakayama S
Rinsho Ketsueki; 1989 May; 30(5):644-9. PubMed ID: 2795878
[TBL] [Abstract][Full Text] [Related]
60. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
